comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 18:07:09 - browse：21

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： House panel takes first step toward fixing drug shortages

WSS

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

How the messy conversation about Dolly changed bioethics

Biogen nominates mother of director’s child to replace him on board

FDA panel to weigh safety of artificial wombs for preterm births

Novo pauses ads for weight loss drug Wegovy amid demand

Biden administration plans revamp of organ transplant system

focus

comprehensive

Wikipedia

Affirmative action in medical school literally saved lives

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Supreme Court strikes down use of affirmative action

How the messy conversation about Dolly changed bioethics

Apple is now the first public company to be valued at $3 trillion

Biogen nominates mother of director’s child to replace him on board

DIEP, the 'gold standard' of breast reconstruction, is under threat

Living organ donors deserve priority status for transplants

Jerome Adams on the need for new antivirals for Covid

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

leisure time

Fed up with FDA, ALS advocates consider a take

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Assistant physicians can help address the primary care shortage

The struggle to figure out which patients 'deserve' Wegovy

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Biden administration plans revamp of organ transplant system

knowledge

hotspot

focus

Wikipedia